|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Argatroban#Patient Counseling Information]] |
| {{Argatroban}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
|
| |
|
| ==Patient Counseling Information==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Inform patients of the risks associated with Argatroban Injection as well as the plan for regular monitoring during administration of the drug. Specifically inform patients to report:
| | [[Category: Anticoagulants]] |
| | |
| * The use of any other products known to affect bleeding
| |
| * Any medical history that may increase the risk for bleeding, including a history of severe hypertension; recent lumbar puncture or spinal anesthesia; major surgery, especially involving the brain, spinal cord, or eye; hematologic conditions associated with increased bleeding tendencies such as congenital or acquired bleeding disorders and gastrointestinal lesions such as ulcerations.
| |
| * Any bleeding signs or symptoms
| |
| * The occurrence of any signs or symptoms of allergic reactions (e.g., airway reactions, skin reactions and vasodilation reactions).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==Reference==
| |
| | |
| {{reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Hematology]] | |
| [[Category:Drugs]] | |